In Vivo Effects Of Ibrutinib On The Migration Of Chronic Lymphocytic Leukemia Cells Differ Between Patients and Reduce The Ability Of The Bone Marrow Microenvironment To Attract The Tumor Cells
Herman SEM, Jones J, Mustafa RZ et al.
Key Points:
This study aimed to assess in vivo effect of ibrutinib on CLL cells' migration.
Pre- and 4 weeks post treatment samples of CLL cells from 9 patients taking ibrutinib analyzed.
Half of patients's treated cells showed increased migration, while in other half decreased migration towards SDF-1/CCL19 mix. Patient's CLL cells showing decrease migration on treatment often had del17p but no difference in regards to IGHV mutation status and no correlation to degree of lymphocytosis observed in vivo.
Similar mixed results obtained when bone marrow aspirate used as chemo-attractant. This lead to hypothesis that Ibrutinib might change bone marrow microenvironment by decreasing chemokine contents which was later confirmed on further evaluation.
Implications:
- Migration of CLL cells from patients on ibrutinib can be inhibited or increased. Bone marrow matrix in patients taking Ibrutinib has reduced capacity to attract CLL cells.
View the original abstract on the ASH website.
